With new biotech startups on the rise and the need for large-scale manufacturing growing, BIB aims to plug the gap with two new facilities P02 and P03, which will be built using the PanFlex® engineering technology.
P02, our facility with a total capacity of over 20,000L that includes GMP production platforms covering mammalian cell culture, microbial fermentation, gene therapy and fill and finish was completed in a record-breaking time. Proving that PanFlex® engineering technology can be deployed successfully with proven results.
P03, our planned GMP facility in Shanghai will have a total minimum capacity of 200,000L, will include the world’s first stainless steel single mammalian cell production line with a capacity of 30,000 liters in total volume, is expected to be completed in the fourth quarter of 2022.
email@example.com today to see how BIB can help you with your biologics manufacturing needs